Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α

Science

Volumn 283, Issue 5400, 1999, Pages 393-397

  Fruman, David A ^a,b   Snapper, Scott B ^b,c,d,e   Yballe, Claudine M ^a,b   Davidson, Laurie ^c   Yu, Jonathan Y ^a,b   Alt, Frederick W ^b,c,d   Cantley, Lewis C ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d CENTER FOR BLOOD RESEARCH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD5 ANTIGEN; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 4; LEUKOSIALIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P55; PROTEIN P85; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; ENZYME ACTIVATION; GROWTH STIMULATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIGENS, CD45; APOPTOSIS; B-LYMPHOCYTES; CATALYTIC DOMAIN; CELL CYCLE; CHIMERA; CHROMONES; ENZYME INHIBITORS; FEMALE; GENE TARGETING; IMMUNOGLOBULINS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; PROTEIN-TYROSINE KINASES; SPLEEN; T-LYMPHOCYTES;

ANIMALIA;

EID: 0033556333     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.283.5400.393     Document Type: Article

References (35)

1. A. Toker and L. C. Cantley, Nature 387, 673 (1997); B. Vanhaesbroeck, S. J. Leevers, G. Panayotou, M. D. Waterfield, Trends in Biochem. Sci. 22, 267 (1997).
2. A. Toker and L. C. Cantley, Nature 387, 673 (1997); B. Vanhaesbroeck, S. J. Leevers, G. Panayotou, M. D. Waterfield, Trends in Biochem. Sci. 22, 267 (1997).
3. J. Domin and M. D. Waterfield, FEBS Lett. 410, 91 (1997).
4. D. A. Fruman, L. C. Cantley, C. L. Carpenter, Genomics 37, 113 (1996).
5. K. Inukai et al., J. Biol. Chem. 271, 5317 (1996); D. A. Antonetti, P. Algenstaedt, C. R. Kahn, Mol. Cell. Biol. 16, 2195 (1996).
6. K. Inukai et al., J. Biol. Chem. 271, 5317 (1996); D. A. Antonetti, P. Algenstaedt, C. R. Kahn, Mol. Cell. Biol. 16, 2195 (1996).
7. J. Yu et al., Mol. Cell. Biol. 18, 1379 (1998).
8. B. C. Duckworth and L. C. Cantley, in Handbook of Lipid Research: Lipid Second Messengers, R. M. Bell and J. H. Exton, Eds. (Plenum, New York, 1996), vol. 8, pp. 125-175.
9. C. Deng, A. Wynshaw-Boris, F. Zhou, A. Kuo, P. Leder, Cell 84, 911 (1996).
10. 7) were electroporated with 20 μg of linearized DNA and subjected to positive selection with G418 (0.4 mg/ml) and negative selection with gancyclovir (1 μM). Two clones (designated 75 and 134) containing heterozygous disruptions of the gene were identified by Southern (DNA) blot analysis with probes flanking the 3′ homology region and with probes internal to both the 5′ and 3′ homology regions. The presence of a single integration event was verified by hybridization with a Neo probe (10). Germ line transmission was obtained with clone 75. For genotyping of mice, we subjected tail DNA to polymerase chain reaction analysis using two primer sets in the same reaction, one set (5′-TCCAAATGAAAAGAACGGCTATC-3′ and 5′-TGTACCAAAGTCACTGAAAAATCTGTT-3′) detecting the endogenous allele, and the other set (5′-AAGATAATATTGAAGCTGTAGGGAAAAA-3′ and 5′-TGTTAAGAAGGGTGAGAACAGAGTACC-3′) detecting a DNA segment in the targeted allele. Homozygous mutant cell lines were isolated by selecting heterozygous cells (clone 75) in increased concentrations of G418 (4.8 mg/ml). These lines and the parental clone 75 were subcloned before injection into RAG2-deficient blastocysts as described (11). Animal experiments were carried out in accordance with institutional guidelines.
11. 32P-labeled DNA probes. Protein immunoblots were prepared with nitrocellulose membranes (Bio-Rad), probed with polyclonal or monoclonal antibodies, and developed with enhanced chemilumiscence reagents (NEN). Monoclonal antibody to p85α (anti-p85α) and polyclonal anti-pan-p85 were purchased from Upstate Biotechnology, Inc., polyctonal anti-p110α from Santa Cruz, and polyclonal anti-p85β was generated by immunizing rabbits with a keyhole limpet hemacyanin (KLH)-conjugated peptide derived from mouse p85β, TyrProPheArgArgGluArgProGluAspLeuGluLeu. Immunoprecipitations were performed with the same antibodies, except that the monoclonal anti-p85α was mixed with a second monoclonal anti-p85α from Transduction Laboratories, and the anti-p110α was a gift of K. Auger.
12. D. A. Fruman, unpublished results.
13. J. Chen, R. Lansford, V. Stewart, F. Young, F. W. Alt, Proc. Natl. Acad. Sci. U.S.A. 90, 4528 (1993).
14. Single-cell suspensions were prepared from lymphoid organs and red blood cells lysed in hypotonic buffer. Cells were stained with fluorescein isothiocyanate (FITC)-, phycoerythrin- and CyChrome-labeled antibodies (Pharmingen and Southern Biotech) and analyzed on a FACScalibur with CellQuest software (Becton-Dickinson) with the use of a live cell gate.
15. A. M. Scharenberg et al., EMBO J. 17, 1961 (1998).
16. K. Salim et al., ibid. 15, 6241 (1996); L. E. Rameh et al., J. Biol. Chem. 272, 22059 (1997); S. Bolland, R. N. Pearse, T. Kurosaki, J. V. Ravetch, Immunity 8, 509 (1998).
17. K. Salim et al., ibid. 15, 6241 (1996); L. E. Rameh et al., J. Biol. Chem. 272, 22059 (1997); S. Bolland, R. N. Pearse, T. Kurosaki, J. V. Ravetch, Immunity 8, 509 (1998).
18. K. Salim et al., ibid. 15, 6241 (1996); L. E. Rameh et al., J. Biol. Chem. 272, 22059 (1997); S. Bolland, R. N. Pearse, T. Kurosaki, J. V. Ravetch, Immunity 8, 509 (1998).
19. S. Tsukada et al., Cell 72, 279 (1993).
20. D. Vetrie et al., Nature 361, 226 (1993).
21. J. D. Thomas et al., Science 261, 355 (1993); D. J. Rawlings et al., ibid., p. 358; J. D. Kerner et al., Immunity 3, 301 (1995).
22. J. D. Thomas et al., Science 261, 355 (1993); D. J. Rawlings et al., ibid., p. 358; J. D. Kerner et al., Immunity 3, 301 (1995).
23. J. D. Thomas et al., Science 261, 355 (1993); D. J. Rawlings et al., ibid., p. 358; J. D. Kerner et al., Immunity 3, 301 (1995).
24. W. N. Khan et al., Immunity 3, 283 (1995).
25. We measured Ig's in serial dilutions of serum using microtiter plates (Dynatech) and antibody pairs specific for different mouse Ig isotypes (Pharmingen). P-Nitrophenylphosphate was used as a substrate for the alkaline phosphatase-conjugated secondary antibodies, and the absorbance at 405 nm was measured in a microplate reader (Molecular Devices).
26. 3H]thymidine (20 μCi/ml, NEN) was added to each well. Cells were harvested 12 hours later with a TomTec plate harvester and counted in a BetaPlate scintillation counter (Wallac).
27. J. E. Hutchcroft and B. E. Bierer, J. Immunol. 156, 4071 (1996); S. C. Ward, Biochem. J. 318, 361 (1996).
28. J. E. Hutchcroft and B. E. Bierer, J. Immunol. 156, 4071 (1996); S. C. Ward, Biochem. J. 318, 361 (1996).
29. K. E. Truitt et al., J. Immunol. 155, 4702 (1995).
30. - cells were excluded, and the percentage of cells with sub-G1 DNA content was quantitated with CellQuest software. Similar results were observed when apoptosis was measured after 18 hours (10).
31. R. T. Woodland, M. R. Schmidt, S. J. Korsmeyer, K. A. Gravel, J. Immunol. 156, 2143 (1996); J. S. Anderson, M. Teutsch, Z. Dong, H. H. Wortis, Proc. Natl. Acad. Sci. U.S.A. 93, 10966 (1996).
32. R. T. Woodland, M. R. Schmidt, S. J. Korsmeyer, K. A. Gravel, J. Immunol. 156, 2143 (1996); J. S. Anderson, M. Teutsch, Z. Dong, H. H. Wortis, Proc. Natl. Acad. Sci. U.S.A. 93, 10966 (1996).
33. H. Suzuki et al., Science 283, 390 (1999).
34. C. L. Carpenter et al., J. Biol. Chem. 265, 19704 (1990).
35. We thank B. Sleckman, S. Thomas, G. Rathbun, and C. Carpenter for suggestions, K. Auger for anti-p110α, J. Lawitts for blastocyst injections, D. Pollard for mouse husbandry and genotyping, D. Kim for help with fibroblast culture, and K. Lee-Fruman for a critical reading of the manuscript. Supported by grants from NIH (to L.C.C., F.W.A., and S.B.S.), a fellowship from the Damon Runyon-Walter Winchell Cancer Research Fund (to D.A.F.), the Leukemia Society of America (to D.A.F.), and the Howard Hughes Medical Institute (to F.W.A.).